SCHEMBL3774296

SCHEMBL3774296

O=C(Cc1ccccc1Oc1ccccc1)N1CCN(CC(=O)N2CCN(C3CCC3)CC2)CC1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.53
ALDH1A1 P00352 3/20 0.53
KMT2A Q03164 2/20 0.47
HRH3 Q9Y5N1 7/20 0.47
SLC6A4 P31645 2/20 0.47
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
SIGMAR1 Q99720 2/20 0.46
ACHE P22303 1/20 0.45
PARP1 P09874 1/20 0.44
MEN1 O00255 1/20 0.44
CCR3 P51677 1/20 0.43
NPC1 O15118 1/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3773641 0.87 KMT2A (0.64) KDM4EALDH1A1KMT2ASIGMAR1MEN1
SCHEMBL3775648 0.86 KDM4E (0.57) KDM4EALDH1A1KMT2AHRH3SIGMAR1
SCHEMBL3774020 0.85 TSHR (0.54) KDM4EALDH1A1KMT2AHRH3SLC6A4
SCHEMBL3767678 0.85 KMT2A (0.53) KDM4EALDH1A1KMT2ASIGMAR1ACHE
SCHEMBL3767582 0.85 ALDH1A1 (0.65) KDM4EALDH1A1KMT2AHRH3SIGMAR1
SCHEMBL3767508 0.84 KDM4E (0.49) KDM4EALDH1A1KMT2AHRH3SLC6A4
SCHEMBL3761258 0.82 KDM4E (0.61) KDM4EALDH1A1HRH3SIGMAR1ACHE
SCHEMBL3763152 0.81 KDM4E (0.55) KDM4EALDH1A1KMT2AHRH3PARP1
SCHEMBL3772003 0.81 CCR3 (0.55) KDM4EALDH1A1KMT2APARP1MEN1
SCHEMBL3770228 0.81 KDM4E (0.55) KDM4EALDH1A1ACHEPARP1CCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 KDM4E 534/4885ALDH1A1 1210/4885KMT2A 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.